<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594928</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3667-CL-112</org_study_id>
    <secondary_id>2020-001427-14</secondary_id>
    <nct_id>NCT04594928</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GLPG3667 in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to assess the safety, tolerability, efficacy,&#xD;
      pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects&#xD;
      with moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Actual">May 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation in subjects with moderate to severe plaque psoriasis.</measure>
    <time_frame>From screening through study completion, an average of 3 months</time_frame>
    <description>To evaluate the safety and tolerability of GLPG3667 compared to placebo in subjects with moderate to severe plaque psoriasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) % change</measure>
    <time_frame>At week 4</time_frame>
    <description>To evaluate signs of clinical efficacy of GLPG3667 compared to placebo in subjects with moderate to severe plaque psoriasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed GLPG3667 plasma trough concentrations (Ctrough).</measure>
    <time_frame>Between Day 1 pre-dose and Day 30</time_frame>
    <description>To characterize the pharmacokinetics (PK) of GLPG3667 in subjects with moderate to severe plaque psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in interleukin 17 [IL-17] levels between treatment groups and time points.</measure>
    <time_frame>Between Day 1 pre-dose and Day 60</time_frame>
    <description>To evaluate blood pharmacodynamics (PD) markers in response to administration of GLPG3667 in subjects with moderate to severe plaque psoriasis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>GLPG3667 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily doses of GLPG3667 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily doses of GLPG3667 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match will be administered as capsules for daily oral use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3667</intervention_name>
    <description>GLPG3667 capsules</description>
    <arm_group_label>GLPG3667 Dose A</arm_group_label>
    <arm_group_label>GLPG3667 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be male or female between 18-64 years of age (extremes included), on the&#xD;
             date of signing the informed consent form (ICF).&#xD;
&#xD;
          -  Subject must be diagnosed (for at least 6 months before screening) of moderate to&#xD;
             severe intensity plaque psoriasis. Subject's plaque psoriasis must be stable, defined&#xD;
             as no flare during the month before the screening visit and no change of the severity&#xD;
             between the screening visit and baseline visit.&#xD;
&#xD;
          -  At screening and at baseline (Day 1, predose), PASI &gt;=12 (moderate to severe) and&#xD;
             plaque-type psoriasis covering at least 10% of total body surface area (BSA).&#xD;
&#xD;
          -  At screening a Physician's Global Assessment (PGA ) score of 3 (&quot;moderate&quot;) or 4&#xD;
             (&quot;severe&quot;).&#xD;
&#xD;
          -  Subject must be considered by dermatologist investigator to be a candidate for&#xD;
             systemic therapy of plaque psoriasis (either na√Øve or history of previous systemic&#xD;
             treatment).&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a known hypersensitivity to investigational product (IP) ingredients or&#xD;
             history of a significant allergic reaction to IP ingredients as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Subjects with psoriasis other than plaque type or complicated psoriasis such as&#xD;
             guttate, erythrodermic, exfoliative, inverse, pustular, palmo plantar, infected, or&#xD;
             ulcerated psoriasis.&#xD;
&#xD;
          -  Subject has evidence of skin conditions other than psoriasis (e.g. eczema) at the time&#xD;
             of screening or baseline visit that would interfere with the evaluation of psoriasis.&#xD;
&#xD;
          -  Subject is unable to discontinue prohibited therapies for the treatment of plaque&#xD;
             psoriasis and/or cannot discontinue phototherapy (ultraviolet B (UVB) or psoralen and&#xD;
             ultraviolet A (PUVA)) before the start of the study up to the end of the study.&#xD;
&#xD;
          -  Subjects with current or a known or suspected history of immunosuppressive condition,&#xD;
             history of invasive opportunistic infections (e.g. human immunodeficiency virus (HIV)&#xD;
             infection, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis,&#xD;
             aspergillosis, or organ or bone marrow transplantation).&#xD;
&#xD;
          -  Subjects having an active clinically significant infection or any infection requiring&#xD;
             oral or systemic therapy within 2 weeks prior screening or subjects currently on any&#xD;
             chronic oral or systemic antiinfective therapy for chronic infection.&#xD;
&#xD;
          -  Subject testing positive for severe acute respiratory syndrome coronavirus-2&#xD;
             (SARS-CoV-2) infection as detected at screening based on real time polymerase chain&#xD;
             reaction (RT-PCR) or at baseline based on Immunoglobulin M (IgM) immunoassay, or&#xD;
             subjects who have been in contact with SARS-CoV-2 infected individuals in the two&#xD;
             weeks prior to first dosing of IP. Subjects presenting any signs or symptoms of&#xD;
             SARS-Cov-2 infection as detected at screening or baseline following careful physical&#xD;
             examination (e.g. cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia,&#xD;
             dysgeusia, anorexia, sore throat, etc.). In addition, any other locally applicable&#xD;
             standard diagnostic criteria may also apply to diagnose SARS-CoV-2 infection.&#xD;
&#xD;
          -  Subjects with evidence of active or latent infection with Mycobacterium tuberculosis&#xD;
             (TB) as defined by:&#xD;
&#xD;
               1. Positive QuantiFERON-TB Gold test result, AND/OR&#xD;
&#xD;
               2. Chest radiograph (posterior anterior view) taken within 12 weeks prior to&#xD;
                  screening, read by a qualified radiologist or pulmonologist, with evidence of&#xD;
                  current active TB or old inactive TB.&#xD;
&#xD;
          -  Subjects with a history of TB who have successful treatment documentation are eligible&#xD;
             for the study.&#xD;
&#xD;
        This list only contains the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Timmis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MC Comac Medical Ltd.</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Early Clinical Trials Unit University Clinical Centre</name>
      <address>
        <city>Gda≈Ñsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Rewerska Diamond Clinic Specjalistyczne Poradnie Lekarskie</name>
      <address>
        <city>Krak√≥w</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumed Sp. z o. o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point</name>
      <address>
        <city>Warsaw</city>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne All-Med</name>
      <address>
        <city>≈Å√≥d≈∫</city>
        <zip>94-048</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

